Home › Epstein-Barr Virus Infections
Epstein-Barr Virus Infections clinical trials recruiting in the U.S.
16 studies for Epstein-Barr Virus Infections are recruiting participants at sites across the United States.
Cities with the most studies
By state
Recently updated studies
Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas
RecruitingPhase 2
Ages 12 and older · All sexes · Updated Sep 22, 2026 · NCT03258567Epstein-Barr Virus (EBV) gH/gL/gp42-Ferritin Nanoparticle Vaccine With or Without gp350-Ferritin in Healthy Adults With or Without EBV Infection
RecruitingPhase 1Healthy volunteers welcome
Ages 18 to 29 · All sexes · Updated Sep 8, 2026 · NCT06908096Third Party Viral Specific T-cells (VSTs)
RecruitingPhase 2
2 Days · All sexes · Updated Sep 4, 2026 · NCT02532452Donor-Derived Viral Specific T-cells (VSTs)
RecruitingPhase 1/2
4 Weeks · All sexes · Updated Sep 4, 2026 · NCT02048332A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
RecruitingPhase 3
All ages · All sexes · Updated Sep 2, 2026 · NCT03394365A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL)
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT06789159Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
RecruitingPhase 1
Ages 18 to 120 · All sexes · Updated Aug 25, 2026 · NCT05389423A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 11, 2026 · NCT05592626R-MVST Cells for Treatment of Viral Infections in Children and Young Adults
RecruitingPhase 1
3 Months – 26 Years · All sexes · Updated Jul 30, 2026 · NCT06926894Genetic Studies of Chronic Active Epstein-Barr Disease
RecruitingObservational study
Ages 1 to 120 · All sexes · Updated Jul 28, 2026 · NCT00032513EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma
RecruitingPhase 1
All ages · All sexes · Updated Jun 25, 2026 · NCT04664179Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma
Recruiting
Ages 18 and older · All sexes · Updated Jun 17, 2026 · NCT06682442TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
RecruitingPhase 1
All ages · All sexes · Updated Jun 11, 2026 · NCT04013802R-MVST Cells for Treatment of Viral Infections
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 10, 2026 · NCT05183490Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity
RecruitingPhase 1/2
1 Month – 65 Years · All sexes · Updated Aug 14, 2025 · NCT06909110EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection
RecruitingPhase 2
1 Month – 79 Years · All sexes · Updated Aug 8, 2025 · NCT03266653From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.